Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 4Lymphoma, T-Cell 4Lymphoma, T-Cell, Cutaneous 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Small Cell Lung Carcinoma 2Sezary Syndrome 2Prostatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2Leukemia, Myeloid, Acute 2Congenital Abnormalities 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1

Interventions

Cyclophosphamide 108Rituximab 62Etoposide 56Methotrexate 52Cytarabine 52Peripheral Blood Stem Cell Transplantation 47Vincristine 45Filgrastim 43fludarabine phosphate 41Radiotherapy 37Mycophenolic Acid 35Doxorubicin 35Tacrolimus 33Busulfan 33Whole-Body Irradiation 32Prednisone 31Methylprednisolone 27Antilymphocyte Serum 27Dexamethasone 26Cyclosporine 26Melphalan 24merphos 20blinatumomab 20Leucovorin 20Granulocyte Colony-Stimulating Factor 16Carmustine 15fludarabine 14Ifosfamide 14Calcium Dobesilate 14CT-P10 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Burkitt Lymphoma × romidepsin × Clear all
NCT00077194 2013-02-11

FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
35 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡